ATLANTA — Device and pharma companies have long griped about issues with the FDA. It seems to be a mantra that runs through the industry. A panel held at the 2012 Georgia Life Sciences Summit on Wednesday spent a bit of time preparing companies for some of the issues that it might encounter along path to regulatory approval, and issues that could occur after commercialization. Read More
